BTAIQ.US BTAIQ

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
0.0120 USD
Close of Nov 14, 2026
0.0040 2.33
Market cap
USD 376K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BTAIQ.US undervalued?

Graham number

The Graham number of BTAIQ cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BTAIQ fundamental analysis

No fundamental analysis for BTAIQ yet.

BTAIQ stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BTAIQ

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational…

Full company profile